N-(2-Carbamyl-aethyl)-piperidiniumchlorid | 92335-84-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(2-Carbamyl-aethyl)-piperidiniumchlorid
• 英文别名: N-(2-Carbamoylethyl)-piperidiniumchlorid；3-Piperidin-1-ylpropanamide;hydrochloride
• CAS: 92335-84-7
• 化学式: C₈H₁₆N₂O*ClH
• 分子量: 192.689
• InChiKey: LJVTUWKFBRVCNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.77
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  46.3
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)<br/>[FR] PYRIDONES SUBSTITUES INHIBITEURS DE LA POLY(ADP-RIBOSE) POLYMERASE (PARP)
  申请人：AVENTIS PHARMA INC

  公开号：WO2005097750A1

  公开（公告）日：2005-10-20

  The present invention discloses and claims a series of 2,3,5-substituted pyridone derivatives as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5'-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.

  本发明公开并声明了一系列如下定义的2,3,5-取代吡啶酮衍生物。本发明还涉及制备这些化合物的方法。本发明的化合物是多聚腺苷酸二磷酸核糖酶（PARP）的抑制剂，因此在制药剂中特别用于治疗和/或预防各种疾病，包括与中枢神经系统和心血管疾病相关的疾病。
• ARYL ALKENAMIDES DERIVATIVES AS MCP-1 ANTAGONISTS
  申请人：——

  公开号：US20020028833A1

  公开（公告）日：2002-03-07

  Aryl alkenamides derivatives of Formula I or a pharmaceutically acceptable salt thereof are novel MCP-1 antagonists and are thus useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection 1 V=O, S, NH or a bond; Ar can be unsubstituted or substituted benzimidazole, phenyl, biphenyl, pyridyl, naphthyl, quinoline, isoquinoline or indole; n=2-6; m=1-3; X=O (oxygen), S (sulfur), ═CH 2 , ═NH or H 2 ; R 1 and R 2 can independently be hydrogen, lower alkyl of from 1-4 carbon atoms, —(CH 2 ) n OR 6 , —(CH 2 ) n NR 3 R 4 , —(CH 2 ) n ′CONR 3 R 4 , —(CH 2 ) n ′COOR 6 , —(CH 2 ) r Ar′, where n′=0-6 r=0-4 R 3 and R 4 can independently be hydrogen, lower alkyl of from 1-4 carbon atoms, —(CH 2 ) n OR 6 , or —(CH 2 ) m —Ar′, which can be unsubstituted or substituted with up to 3 substitutents, where “Ar′” is phenyl, pyridyl, or indole; R 3 and R 4 may also be taken together to form a cyclic ring of 3-8 atoms which may also contain oxygen or the group NR 5 where R 5 can be hydrogen, lower alkyl of from 1-4 carbon atoms, cycloalkyl of from 5-12 carbon atoms, or —(CH 2 ) m -Phenyl, which can be unsubstituted or substituted with up to 3 substitutents; R 6 can be hydrogen, lower alkyl or (CH 2 ) m -Phenyl; m=1-3; R 1 and R 2 may be also taken together to form a ring of 3-8 atoms which may also contain oxygen or the group NR 5 , which ring may be substituted on one or more carbon atoms with the group NR 3 R 4 ; the subtituents are defined as: halogen, nitro, CF 3 , alkyl of from 1-12 carbon atoms; —(CH 2 ) r OR 6 —(CH 2 ) r NR 3 R 4 —(CH 2 ) r CONR 3 R 4 —(CH 2 ) r C(O)OR 6 or —(CH 2 ) r SO 2 —OR 6 ; R 7 , R 8 , R 9 and R 10 can each independently be hydrogen, lower alkyl or aryl; and R 7 and R 8 or R 9 and R 10 or X or R 2 when taken together can form a 5-7 membered ring including cycloalkyl, cycloalkenyl, aryl, or heteroaryl containing nitrogen, oxygen or sulfur.

  公式I的芳基烯酰胺衍生物或其药学上可接受的盐是新型MCP-1拮抗剂，因此在治疗炎症、动脉粥样硬化、再狭窄和免疫紊乱，如关节炎和移植排斥方面有用。其中，V=O，S，NH或键；Ar可以是未取代或取代苯并咪唑、苯基、联苯基、吡啶基、萘基、喹啉、异喹啉或吲哚；n=2-6；m=1-3；X=O（氧）、S（硫）、═CH2、═NH或H2；R1和R2可以独立地是氢、1-4碳原子的低烷基、—（ ）nOR6、—（ ）nNR3R4、—（ ）n′CONR3R4、—（ ）n′COOR6、—（ ）rAr′，其中n=0-6，r=0-4；R3和R4可以独立地是氢、1-4碳原子的低烷基、—（ ）nOR6或—（ ）m—Ar′，其中“Ar′”可以是未取代或取代的苯基、吡啶基或吲哚，最多可以带有3个取代基；R3和R4也可以结合成为3-8个原子的环，该环也可以包含氧或基团NR5，其中R5可以是氢、1-4碳原子的低烷基、5-12碳原子的环烷基或—（ ）m-苯基，最多可以带有3个取代基；R6可以是氢、低烷基或（ ）m-苯基；m=1-3；R1和R2也可以结合成为3-8个原子的环，该环也可以包含氧或基团NR5，在其中一个或多个碳原子上取代基团NR3R4；取代基团的定义为：卤素、硝基、CF3、1-12碳原子的烷基；—（ ）rOR6、—（ ）rNR3R4、—（ ）rCONR3R4、—（ ）rC（O）OR6或—（ ）rSO2—OR6；R7、R8、R9和R10可以各自独立地是氢、低烷基或芳基；当R7和R8或R9和R10或X或R2结合在一起时，可以形成一个包含氮、氧或硫的5-7个成员的环，包括环烷基、环烯基、芳基或杂芳基。
• SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)
  申请人：Weintraub M. Philip

  公开号：US20070032489A1

  公开（公告）日：2007-02-08

  The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R 1 , R 2 , R 3 and R 4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5′-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.

  本发明涉及一系列公式I的2,3,5-取代吡啶酮衍生物，其中R，R1，R2，R3和R4如本文所定义。本发明还涉及制备这些化合物的方法。本发明的化合物是聚腺苷酸二磷酸核糖聚合酶（PARP）的抑制剂，因此在治疗和/或预防各种疾病，包括与中枢神经系统和心血管疾病有关的疾病方面，具有药物学上的用途。
• US6458806B1
  申请人：——

  公开号：US6458806B1

  公开（公告）日：2002-10-01
• US8173682B2
  申请人：——

  公开号：US8173682B2

  公开（公告）日：2012-05-08